Zai Lab (ZLAB) Getting Positive News Coverage, Analysis Shows

Media headlines about Zai Lab (NASDAQ:ZLAB) have trended positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zai Lab earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.9286100203736 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Several equities analysts have commented on the stock. J P Morgan Chase & Co assumed coverage on shares of Zai Lab in a research report on Monday, October 16th. They issued a “neutral” rating and a $32.00 price target for the company. Citigroup assumed coverage on shares of Zai Lab in a research report on Monday, October 16th. They issued a “buy” rating for the company. Finally, Leerink Swann assumed coverage on shares of Zai Lab in a research report on Monday, October 16th. They issued an “outperform” rating and a $42.00 price target for the company.

Zai Lab (NASDAQ ZLAB) opened at $25.74 on Thursday. Zai Lab has a 1 year low of $23.80 and a 1 year high of $35.74.

TRADEMARK VIOLATION WARNING: “Zai Lab (ZLAB) Getting Positive News Coverage, Analysis Shows” was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/12/07/zai-lab-zlab-getting-positive-news-coverage-analysis-shows.html.

Zai Lab Company Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.

Insider Buying and Selling by Quarter for Zai Lab (NASDAQ:ZLAB)

What are top analysts saying about Zai Lab Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zai Lab Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit